- Home
- STK vs TBPH Comparison
STK vs TBPH Comparison
Compare STK & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STK | TBPH |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.8M | 824.9M |
| IPO Year | 2009 | 2013 |
Fundamental Metrics
Financial Performance| Metric | STK | TBPH |
|---|---|---|
| Price | $48.82 | $16.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.40 |
| AVG Volume (30 Days) | 50.4K | ★ 297.6K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | N/A | $8.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.00 | $9.10 |
| 52 Week High | $52.04 | $21.03 |
Technical Indicators
Market Signals| Indicator | STK | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 54.43 | 43.09 |
| Support Level | $38.21 | $16.14 |
| Resistance Level | $52.04 | $17.21 |
| Average True Range (ATR) | 1.31 | 0.38 |
| MACD | -0.46 | -0.10 |
| Stochastic Oscillator | 30.15 | 16.81 |
Price Performance
Historical ComparisonAbout STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.